Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/18/2009

van; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme and Kuvan; actual sales of Aldurazyme, Naglazyme and Kuvan; Merck Serono's activities related to Kuvan; the results of the final analysis of the ASPEN trial by La Jolla Pharmaceuticals; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

    Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

     Contact:

     Investors                         Media
     Eugenia Shen                      Susan Berg
     BioMarin Pharmaceutical Inc.      BioMarin Pharmaceutical Inc.
     (415) 506-6570                    (415) 506-6594



                BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

                         CONSOLIDATED BALANCE SHEETS
                          December 31, 2007 and 2008
             (In thousands, except for share and per shar
'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
2. BioMarin to Present at the Piper Jaffray Healthcare Conference
3. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
4. BioMarin to Present at the Credit Suisse Healthcare Conference
5. BioMarin Announces Third Quarter 2008 Financial Results
6. BioMarin Corrects Information Included in Bloomberg Article
7. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
8. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
9. BioMarin to Present at the Citi Biotech Day
10. BioMarin Announces Roll-Out of National PKU Registry
11. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Greenville, SC (PRWEB) August 22, 2014 ... that indisputable acknowledgement is a national disgrace. Furthermore, ... part in establishing the current, deplorable state of ... outlined "5 great mistakes," to merely serve as ... convey the extent of colossal failure(s) that have ...
(Date:8/21/2014)... team including DESY scientists has observed tiny quantum vortices ... in the journal Science that the exotic ... nanodroplets. It is the first time that the quantum ... of what is known as superfluid helium, have been ... expectations," says Andrey Vilesov of the University of Southern ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere Biosciences, ... their Nutraceutical "TELO-20 for Dogs" with Telomerase ... supplement in the world for dogs. Telomeres are ... chromosome in the body. A wealth of ground-breaking ... in Telomere Science and Aging, including Nobel laureates, ...
(Date:8/21/2014)... 2014 OTC Markets Group Inc. ... biotechnology company, on its approval to list on ... OTCQX®, the best marketplace for established U.S. and ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... of its growth strategy and achievement of this ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... BioSciences, Inc. (OTC Bulletin Board: GNLK ... that it ranked number 33 on Technology Fast 500 ... growing technology, media, telecommunications, life sciences and clean technology ... the period 2006-2010. GeneLink,s chief executive ...
... Inc ., a late-stage epigenetics oncology company, announced today that members ... BIO Investor Forum , San Francisco, CA, October ... Target , Panel Discussion: HDACi and Their Progress in the Clinic, ... Healthcare Conference , New York, NY, November 16, 1:30 PM ET ...
... 24, 2011 Modern Plastics, one of the largest ... plastics, has become ISO 13485-2003 certified for the distribution ... Resin. "This is an extraordinary achievement ... service and quality," said Bing J. Carbone, President at ...
Cached Biology Technology:GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 2GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 3Syndax Pharmaceuticals to Present at Upcoming Fall Conferences 2
(Date:8/21/2014)... of researchers at Louisiana Tech University has ... consumer-grade 3D printers and materials to fabricate ... and chemotherapeutic compounds for targeted drug delivery. ... and research faculty from Louisiana Tech,s biomedical ... create filament extruders that can make medical-quality ...
(Date:8/21/2014)... resulting in severe abdominal pain, vomiting and systemic inflammation. ... diagnosed with the disease resulting in 1000 deaths. There ... intravenous fluid and nutritional support. , Dr Jason ... the research, said "The major causes of pancreatitis include ... intake combined with a high fat diet. In fact, ...
(Date:8/20/2014)... Researchers at Huntsman Cancer Institute (HCI) at the University ... the gene that encodes BCR-ABL, the unregulated enzyme driving ... the American Cancer Society, nearly 6,000 new cases of ... in use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL ... not cure CML but control it in a way ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... the Smithsonian Institution and the Hawaii Institute of Marine ... created the first frozen bank for Hawaiian corals in ... preserve their diversity in Hawaii. Mary Hagedorn, an adjunct ... the Smithsonian Conservation Biology Institute, leads the laboratory at ...
... underlay many cancers. Rui Martinho at the Instituto Gulbenkian ... in Ghent (Belgium) and Bergen (Norway) will use the ... identified in the test-tube, impact on the way cells ... the Association for International Cancer Research (AICR), will provide ...
... of an old antibiotic may help diabetics avoid a stroke ... researchers report. Minocycline, a drug already under study at ... blood vessels in the brain that increases their stroke risk ... Dr. Adviye Ergul, physiologist in the MCG Schools of Medicine ...
Cached Biology News:Smithsonian scientists help create first frozen repository for Hawaiian coral 2Understanding cancer using the fruit fly 2Antibiotic may reduce stroke risk and injury in diabetics 2
... Desselberger (1995) • This book is ... classical and molecular techniques currently used ... and analysis of virus-specific antibodies and ... presented covering immunoassays, blotting and hybridization ...
Bovine Serum...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
2.0 GHz Compaq Computer with 512 MB RAM, 32 MB AGP Graphics Card, 40 GB Hard Drive, 1 Serial Port & Open PCI Slot, Windows 2000 OS, MS Office, CD Read/Writer and 18 Flat Panel Monitor...
Biology Products: